Arch Biopartners begins patient dosing at Toronto General Hospital in phase II trial of LSALT peptide targeting cardiac surgery-associated acute kidney injury

Arch Biopartners Inc. (Arch), a late-stage clinical trial company, announced that the first patient has successfully completed dosing at Toronto General Hospital (TGH), part of the University Health Network

To access the full article, please log in or subscribe.